Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Takeda's Qdenga receives India's first dengue vaccine approval for dengue virus prevention across all four serotypes
Vaccine, infectious disease, live-attenuated vaccine, dengue, pediatric population - Read more

JCR Pharmaceuticals wins UAE marketing authorization for IZCARGO (pabinafusp alfa), a blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome
Protein therapy, neurological, enzyme replacement therapy, Hunter syndrome, blood-brain barrier, rare disease - Read more

Bristol Myers Squibb, Nvidia expand AI collaboration to build “most powerful” life sciences AI infrastructure
Research collaboration, AI/ML, drug discovery, R&D - Read more

Menarini Asia-Pacific, Pharmacosmos partner to register and commercialize first-in-class oncology therapy Cosela across Asia-Pacific
Licensing deal, oncology, small molecule, commercialization - Read more

Halozyme Therapeutics, Incyte collaborate on subcutaneous formulations of INCA033989 using ENHANZE technology
Licensing deal, oncology, monoclonal antibody, milestone payments, royalties - Read more

Managing investigator grants across large portfolios isn't just a tracking problem — it's a trial oversight issue. Limited visibility into site and procedural-level liabilities makes it nearly impossible to accurately forecast investigator expenses, which can exceed 50% of a trial's budget. Incorrect billing and surprise invoices follow. 

The good news: sponsors already have the data they need to get this under control. 

Join Auxilius on July 29th at 10am ET to learn how leading pharma and biotech teams are managing investigator spend using data they already have, building data taxonomies to organize and harmonize it, and using automation to operate at scale.

Register here

Gilead Sciences, Merck & Co.'s (islatravir/lenacapavir) Ph3 data support first weekly oral human immunodeficiency virus treatment
Small molecule, infectious disease, HIV, combination therapy, viral suppression, weekly oral treatment - Read more

Enterome's EO2463 Ph2 data link CD8 T-cell expansion to progression-free survival in indolent non-Hodgkin lymphoma
Vaccine, cancer, peptide vaccine, non-Hodgkin lymphoma, CD8 T-cell expansion, follicular lymphoma - Read more

Belite Bio's tinlarebant meets Ph3 secondary endpoints, showing stable retinal biomarkers in Stargardt disease type 1
Small molecule, ophthalmology, retinal disease, Stargardt disease, RBP4 inhibitor, tinlarebant - Read more

Center for Therapeutic Genetics launches at Broad Institute, targeting personalized gene therapies for rare childhood diseases
Gene therapy, rare disease, neurological, strategic - Read more

Lupin spins out Kaveri Therapeutics with two clinical-stage cancer assets, valued at $1.6M
Licensing deal, oncology, small molecule, spinout, equity investment - Read more

Novartis returns to Q2 sales growth with Kisqali, Kesimpta driving gains despite Entresto generic headwinds
Small molecule, oncology, revenue impact, competitive - Read more

Axiom Biosciences plans $150-200M Hong Kong IPO to advance regenerative medicines pipeline
Regenerative medicine, stem cell therapy, neurological, rare disease, clinical-stage - Read more

Rege Nephro secures $10.6M via J-KISS financing to advance RN-014 toward commercialization
Clinical-stage, rare disease, small molecule, cell therapy, kidney disease - Read more

Brenus Pharma raises €11M ($12.6M) Series A extension, advancing immuno-oncology platform for solid tumors
Immuno-oncology, platform technology, solid tumors, preclinical - Read more

Alliance for Building Better Medicine secures $15.97M federal investment to launch domestic pharmaceutical End-to-End Commercialization Project
Small molecule, critical care, manufacturing, federal funding - Read more

Tempus AI to acquire Personalis for $1.5B, expanding cancer MRD diagnostics portfolio
Liquid biopsy, oncology, major transaction, strategic - Read more

Kowa Pharmaceutical Asia acquires HST Medical to expand Singapore health supplement brand globally
Health supplements, wellness, strategic, major transaction - Read more

Novartis maintains geography-agnostic dealmaking strategy, prioritizing science amid Entresto patent cliff challenges
Small molecule, cardiovascular, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novartis discontinues Ph2 Lu-NeoB (Lutetium-NeoB) radioligand therapy targeting gastrin-releasing peptide receptor in solid tumors
Radioligand therapy, cancer, solid tumors, GRPR target, combination therapy - Read more

Agios Pharmaceuticals discontinues (tebapivat) Ph2 development in sickle cell disease after lackluster pyruvate kinase activator data
Small molecule, hematological disease, pyruvate kinase activator, sickle cell disease, hemolytic anemia - Read more

Novo Nordisk sues Eli Lilly over "false and misleading" GLP-1 ads comparing Zepbound, Wegovy efficacy
GLP-1 agonist, metabolic disease, competitive, regulatory - Read more

Moderna countersues CureVac in Delaware court, alleging breach of agreement over COVID vaccine patent lawsuit
mRNA vaccine, infectious disease, intellectual property dispute, competitive - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here